CO5150204A1 - METHOD OF INCREASING THE OSEO VOLUME UNDERSTANDING THE ADMINISTRATION OF A SELECTIVE FP AGONIST THAT DOESN'T NATURALLY OCCUR AND A SELECTIVE EP1 AGONIST THAT DOES NOT NATURALLY OCCUR TO A SUBJECT THAT REQUIRES SUCH TREATMENT - Google Patents
METHOD OF INCREASING THE OSEO VOLUME UNDERSTANDING THE ADMINISTRATION OF A SELECTIVE FP AGONIST THAT DOESN'T NATURALLY OCCUR AND A SELECTIVE EP1 AGONIST THAT DOES NOT NATURALLY OCCUR TO A SUBJECT THAT REQUIRES SUCH TREATMENTInfo
- Publication number
- CO5150204A1 CO5150204A1 CO00015566A CO00015566A CO5150204A1 CO 5150204 A1 CO5150204 A1 CO 5150204A1 CO 00015566 A CO00015566 A CO 00015566A CO 00015566 A CO00015566 A CO 00015566A CO 5150204 A1 CO5150204 A1 CO 5150204A1
- Authority
- CO
- Colombia
- Prior art keywords
- agonist
- selective
- naturally occur
- administration
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se relaciona con nuevos métodos para aumentar el volumen óseo que comprenden la administración de un agonista FP selectivo que no ocurre naturalmente y un agonista EP1 selectivo que no ocurre naturalmente a un sujeto que requiere de tal tratamiento. Esta invención se refiere adicionalmente a un método para tratar o evitar trastornos óseos que comprenden la administración de un agonista FP selectivo que no ocurre naturalmente y un agonista EP1 selectivo que no ocurre naturalmente a un sujeto que requiere de tal tratamiento.The present invention relates to new methods for increasing bone volume that comprise the administration of a non-naturally occurring selective FP agonist and a selective EP1 agonist that does not occur naturally to a subject requiring such treatment. This invention further relates to a method of treating or avoiding bone disorders comprising the administration of a naturally occurring non-naturally occurring FP agonist and a selective EP1 agonist that does not occur naturally to a subject requiring such treatment.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12292199P | 1999-03-05 | 1999-03-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5150204A1 true CO5150204A1 (en) | 2002-04-29 |
Family
ID=22405645
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00015566A CO5150204A1 (en) | 1999-03-05 | 2000-03-03 | METHOD OF INCREASING THE OSEO VOLUME UNDERSTANDING THE ADMINISTRATION OF A SELECTIVE FP AGONIST THAT DOESN'T NATURALLY OCCUR AND A SELECTIVE EP1 AGONIST THAT DOES NOT NATURALLY OCCUR TO A SUBJECT THAT REQUIRES SUCH TREATMENT |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU3385900A (en) |
CO (1) | CO5150204A1 (en) |
WO (1) | WO2000051616A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000051585A2 (en) * | 1999-03-05 | 2000-09-08 | The Procter & Gamble Company | Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume |
EP2305304A4 (en) | 2008-04-28 | 2011-08-10 | Nat University Corp Hamamatsu University School Of Medicine | Immunopotentiating agent comprising ep1 agonist |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3982016A (en) * | 1975-08-06 | 1976-09-21 | Pfizer Inc. | Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters |
US4621100A (en) * | 1981-09-25 | 1986-11-04 | The Upjohn Company | Treatment of osteoporosis with prostaglandins |
US5409911A (en) * | 1992-09-11 | 1995-04-25 | Merck & Co., Inc. | Prostaglandin analog for treating osteoporosis |
AU693698B2 (en) * | 1995-05-18 | 1998-07-02 | Allergan, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylakenyl derivatives as therapeutic agents for the treatment of ocular hypertension |
US5741810A (en) * | 1996-02-29 | 1998-04-21 | Allergan | Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents |
ID24827A (en) * | 1997-09-09 | 2000-08-24 | Procter & Gamble | BONE VOLUME IMPROVEMENT METHOD USING NON-NATURAL SELECTIVE FP AGONISTS |
-
2000
- 2000-03-01 AU AU33859/00A patent/AU3385900A/en not_active Abandoned
- 2000-03-01 WO PCT/US2000/005161 patent/WO2000051616A1/en active Application Filing
- 2000-03-03 CO CO00015566A patent/CO5150204A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU3385900A (en) | 2000-09-21 |
WO2000051616A1 (en) | 2000-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9811780A (en) | Bone volume increase method using non-naturally occurring selective fp agonists | |
IL280818B (en) | Methods for producing alpha-galactosidase a compositions | |
MY129189A (en) | Prostaglandin agonists and their use to treat bone disorders | |
MXPA04008068A (en) | Method for administering glp-1 molecules. | |
DE69626660D1 (en) | 2-alkylpyrrolidine | |
PL349028A1 (en) | Cancer treatment composition and method using natural plant essential oils | |
AU3084302A (en) | Peptide yy and peptide yy agonists for treatment of metabolic disorders | |
MY141384A (en) | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | |
PT867178E (en) | USE OF AGONISTS NOT ALOSTERICOS DE GABA FOR THE TREATMENT OF SLEEP DISORDERS | |
AP2001002129A0 (en) | 5HT1 receptor agonists and metoclopramide for the treatment of migrane. | |
AP9801269A0 (en) | Prostaglandin agonists. | |
BR9911917A (en) | Compositions comprising gaba and caffeine analogs | |
DK1420827T3 (en) | 5-CNAC sp, oral administration agent for parathyroid hormone fragments | |
EP1173470A4 (en) | Treatment of bone disorders with adrenomedullin or adrenomedullin agonists | |
EA200300461A1 (en) | TREATMENT OF T-CELL DISORDERS | |
MXPA94009086A (en) | Therapeutic substituted guanidines. | |
EP1441718A4 (en) | Carbinols for the treatment of neuropathic dysfunction | |
MXPA03010406A (en) | Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg. | |
AP1896A (en) | The method of treating cancer | |
JO3446B1 (en) | Method for treating primary insomnia | |
HK1112738A1 (en) | Arylsulfonamides and analogues as well as use for the treatment of neuro- degenerative disorders | |
CO5150204A1 (en) | METHOD OF INCREASING THE OSEO VOLUME UNDERSTANDING THE ADMINISTRATION OF A SELECTIVE FP AGONIST THAT DOESN'T NATURALLY OCCUR AND A SELECTIVE EP1 AGONIST THAT DOES NOT NATURALLY OCCUR TO A SUBJECT THAT REQUIRES SUCH TREATMENT | |
PL370361A1 (en) | Alkyl urea retinoid agonists i | |
GB2331301C (en) | Galanin | |
MXPA02001204A (en) | Calcilytic compounds. |